A Polish Radio piece argues that Ozempic and similar weight-loss drugs are creating health problems that get little attention.
Recap by typeshit. Full story at www.polskieradio.pl.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Revenue rose 48% on Mounjaro and Zepbound demand, and Lilly raised 2026 guidance to $85B to $87B. CEO David Ricks calls retatrutide the next growth driver.
A pharmacy attorney explains why boards and plaintiffs now treat USP standards as the baseline, and why research use only labels won't shield sloppy compounding.
Loading…